{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:54:28Z","timestamp":1792011268791,"version":"4.4.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007653","name":"Universit\u00e4tsklinikum Jena","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.tranon.2020.100801","type":"journal-article","created":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T05:18:47Z","timestamp":1590297527000},"page":"100801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Evaluation of Somatostatin and CXCR4 Receptor Expression in a Large Set of Prostate Cancer Samples Using Tissue Microarrays and Well-Characterized Monoclonal Antibodies"],"prefix":"10.1016","volume":"13","author":[{"given":"Christoph","family":"Werner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Dirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Dahmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Oliver","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Lupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2020.100801_bb0005","doi-asserted-by":"crossref","first-page":"a030361","DOI":"10.1101\/cshperspect.a030361","article-title":"The epidemiology of prostate cancer","volume":"8","author":"Pernar","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.tranon.2020.100801_bb0010","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1177\/1557988318798279","article-title":"Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location","volume":"12","author":"Taitt","year":"2018","journal-title":"Am. J. Mens Health"},{"key":"10.1016\/j.tranon.2020.100801_bb0015","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/jama.2018.0154","article-title":"Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial","volume":"319","author":"Martin","year":"2018","journal-title":"JAMA."},{"key":"10.1016\/j.tranon.2020.100801_bb0020","first-page":"329","article-title":"The treatment of localized prostate cancer in everyday practice in Germany","volume":"113","author":"Herden","year":"2016","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.tranon.2020.100801_bb0025","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.tranon.2020.100801_bb0030","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2018.0587","article-title":"Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9-10 prostate cancer","volume":"319","author":"Kishan","year":"2018","journal-title":"JAMA."},{"key":"10.1016\/j.tranon.2020.100801_bb0035","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/1060028014565444","article-title":"Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases","volume":"49","author":"McGann","year":"2015","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.tranon.2020.100801_bb0040","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.semnuclmed.2019.02.003","article-title":"Radionuclide therapy of metastatic prostate cancer","volume":"49","author":"Kratochwil","year":"2019","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.tranon.2020.100801_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmir.2019.05.006","article-title":"Radium-223 in metastatic castration-resistant prostate cancer: clinical development and use in contemporary practice","author":"Morgan","year":"2019","journal-title":"J Med Imag Rad Sci"},{"key":"10.1016\/j.tranon.2020.100801_bb0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/1078-0432.CCR-15-0820","article-title":"New strategies in prostate cancer: prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy","volume":"22","author":"Haberkorn","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2020.100801_bb0055","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/RLU.0000000000001240","article-title":"Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration-resistant prostate cancer","volume":"41","author":"Rahbar","year":"2016","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.tranon.2020.100801_bb0060","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.2967\/jnumed.117.191023","article-title":"177Lu-PSMA radioligand therapy for prostate cancer","volume":"58","author":"Fendler","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tranon.2020.100801_bb0065","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00259-016-3481-7","article-title":"177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment","volume":"44","author":"Yadav","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.tranon.2020.100801_bb0070","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1053\/j.semnuclmed.2019.02.008","article-title":"PSMA-targeted radiopharmaceuticals for imaging and therapy","volume":"49","author":"Wester","year":"2019","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.tranon.2020.100801_bb0075","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.beem.2015.10.005","article-title":"Peptide receptor radionuclide therapy of neuroendocrine tumours","volume":"30","author":"Brabander","year":"2016","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tranon.2020.100801_bb0080","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.hoc.2015.09.009","article-title":"Peptide receptor radionuclide therapy in the treatment of neuroendocrine tumors","volume":"30","author":"Kwekkeboom","year":"2016","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"10.1016\/j.tranon.2020.100801_bb0085","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40336-018-0267-x","article-title":"Peptide receptor radionuclide therapy for neuroendocrine tumors","volume":"6","author":"Yusuf","year":"2018","journal-title":"Clin. Transl. Imag."},{"key":"10.1016\/j.tranon.2020.100801_bb0090","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.clinimag.2019.04.006","article-title":"Molecular imaging and therapy of somatostatin receptor positive tumors","volume":"56","author":"Ivanidze","year":"2019","journal-title":"Clin. Imag."},{"key":"10.1016\/j.tranon.2020.100801_bb0095","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ymeth.2017.09.002","article-title":"Chemokine receptor \u2014 directed imaging and therapy","volume":"130","author":"Buck","year":"2017","journal-title":"Methods"},{"key":"10.1016\/j.tranon.2020.100801_bb0100","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s12149-018-1290-8","article-title":"CXCR4-directed theranostics in oncology and inflammation","volume":"32","author":"Kircher","year":"2018","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.tranon.2020.100801_bb0105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1078-1439(01)00173-9","article-title":"Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines","volume":"7","author":"Dizeyi","year":"2002","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.tranon.2020.100801_bb0110","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/pros.10121","article-title":"Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer","volume":"53","author":"Hansson","year":"2002","journal-title":"Prostate"},{"key":"10.1016\/j.tranon.2020.100801_bb0115","doi-asserted-by":"crossref","first-page":"723831","DOI":"10.1155\/2009\/723831","article-title":"Tumoral prostate shows different expression pattern of somatostatin receptor 2 (SSTR2) and phosphotyrosine phosphatase SHP-1 (PTPN6) according to tumor progression","volume":"2009","author":"Cariaga-Martinez","year":"2009","journal-title":"Adv. Urology"},{"key":"10.1016\/j.tranon.2020.100801_bb0120","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/j.1464-410X.2010.09238.x","article-title":"Immunohistochemical expression of somatostatin receptor subtypes in prostate tissue from cystoprostatectomies with incidental prostate cancer","volume":"106","author":"Morichetti","year":"2010","journal-title":"BJU Int."},{"key":"10.1016\/j.tranon.2020.100801_bb0125","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/039463201002300213","article-title":"Immunohistochemical expression and localizationof somatostatin receptor subtypes in prostate cancer with neuroendocrine differentiation","volume":"23","author":"Morichetti","year":"2010","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.tranon.2020.100801_bb0130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1155\/2010\/532094","article-title":"Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer","volume":"33","author":"Mazzucchelli","year":"2010","journal-title":"Anal. Cell Pathol. \/ Cell Oncol."},{"key":"10.1016\/j.tranon.2020.100801_bb0135","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/PAT.0b013e32835bae76","article-title":"Somatostatin receptor expression in prostate carcinoma: the urological pathologist's role in the era of personalised medicine","volume":"45","author":"Montironi","year":"2013","journal-title":"Pathology"},{"key":"10.1016\/j.tranon.2020.100801_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100469","article-title":"Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse","volume":"9","author":"Hennigs","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2020.100801_bb0145","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/jcb.10522","article-title":"Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo","volume":"89","author":"Sun","year":"2003","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.tranon.2020.100801_bb0150","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1096\/fj.03-0935fje","article-title":"Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis","volume":"18","author":"Darash-Yahana","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.tranon.2020.100801_bb0155","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.bbrc.2004.06.013","article-title":"Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis","volume":"320","author":"Mochizuki","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tranon.2020.100801_bb0160","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1158\/1078-0432.CCR-07-0859","article-title":"CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility","volume":"13","author":"Hirata","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2020.100801_bb0165","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1349-7006.2007.00712.x","article-title":"Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer","volume":"99","author":"Akashi","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.tranon.2020.100801_bb0170","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.4161\/cbt.7.11.6862","article-title":"Tumor cell-specific blockade of CXCR4\/SDF-1 interactions in prostate cancer cells by hTERT promoter induced CXCR4 knockdown: A possible metastasis preventing and minimizing approach","volume":"7","author":"Xing","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.tranon.2020.100801_bb0175","doi-asserted-by":"crossref","first-page":"607","DOI":"10.4111\/kju.2011.52.9.607","article-title":"Correlation between chemokine receptor CXCR4 expression and prognostic factors in patients with prostate cancer","volume":"52","author":"Jung","year":"2011","journal-title":"Korean J. Urol."},{"issue":"2 Pt 2","key":"10.1016\/j.tranon.2020.100801_bb0180","first-page":"E51","article-title":"Evaluation of nuclear factor \u03baB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610","volume":"108","author":"Okera","year":"2011","journal-title":"BJU Int."},{"key":"10.1016\/j.tranon.2020.100801_bb0185","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1593\/neo.12324","article-title":"CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy","volume":"14","author":"Domanska","year":"2012","journal-title":"Neoplasia"},{"key":"10.1016\/j.tranon.2020.100801_bb0190","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00345-014-1299-0","article-title":"CXCR4 is highly expressed at the tumor front but not in the center of prostate cancers","volume":"33","author":"Delongchamps","year":"2015","journal-title":"World J. Urol."},{"key":"10.1016\/j.tranon.2020.100801_bb0195","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/pros.23007","article-title":"CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models","volume":"75","author":"Gravina","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.tranon.2020.100801_bb0200","first-page":"2706","article-title":"SDF-1\/CXCR4 axis promotes prostate cancer cell invasion and bone metastasis through p38, NF\u03baB and HIF-1\u03b1 pathways","volume":"9","author":"Diao","year":"2016","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.tranon.2020.100801_bb0205","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1038\/s41598-018-20765-8","article-title":"The MRPS18-2 protein levels correlate with prostate tumor progression and it induces CXCR4-dependent migration of cancer cells","volume":"8","author":"Mushtaq","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tranon.2020.100801_bb0210","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1210\/jc.2008-1063","article-title":"Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1","volume":"93","author":"Fischer","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tranon.2020.100801_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004069","article-title":"Reassessment of CXCR4 chemokine receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-2","volume":"3","author":"Fischer","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2020.100801_bb0220","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000329876","article-title":"Reassessment of sst5 somatostatin receptor expression in normal and neoplastic human tissues using the novel rabbit monoclonal antibody UMB-4","volume":"94","author":"Lupp","year":"2011","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.tranon.2020.100801_bb0225","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000337659","article-title":"Reassessment of sst3 somatostatin receptor expression in normal and neoplastic human tissues using the novel rabbit monoclonal antibody UMB-4","volume":"96","author":"Lupp","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.tranon.2020.100801_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.regpep.2013.02.001","article-title":"Reevaluation of sst1 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-7","volume":"183","author":"Lupp","year":"2013","journal-title":"Regul. Pept."},{"key":"10.1016\/j.tranon.2020.100801_bb0235","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/PAS.0b013e31823d07f3","article-title":"Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting","volume":"36","author":"K\u00f6rner","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.tranon.2020.100801_bb0240","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.regpep.2013.10.007","article-title":"Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies","volume":"187","author":"Lambertini","year":"2013","journal-title":"Regul. Pept."},{"key":"10.1016\/j.tranon.2020.100801_bb0245","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.humpath.2013.08.007","article-title":"Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies","volume":"45","author":"Chinezu","year":"2014","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.tranon.2020.100801_bb0250","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.mpdhp.2009.01.010","article-title":"How to make tissue microarrays","volume":"15","author":"Parsons","year":"2009","journal-title":"Diagnostic Histopathol."},{"key":"10.1016\/j.tranon.2020.100801_bb0255","first-page":"138","article-title":"Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue","volume":"8","author":"Remmele","year":"1987","journal-title":"Pathologe"},{"key":"10.1016\/j.tranon.2020.100801_bb0260","doi-asserted-by":"crossref","first-page":"719","DOI":"10.6004\/jnccn.2014.0073","article-title":"Neuroendocrine prostate cancer: Subtypes, biology, and clinical outcomes","volume":"12","author":"Aggarwal","year":"2014","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.tranon.2020.100801_bb0265","first-page":"145","article-title":"Somatostatin receptors over-expression in castration resistant prostate cancer detected by PET\/CT: preliminary report of in six patients","volume":"3","author":"Savelli","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.tranon.2020.100801_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/RLU.0000000000001424","article-title":"PET\/CT with 68Ga-DOTA-TATE for diagnosis of neuroendocrine differentiation in patients with castrate-resistant prostate cancer","volume":"42","author":"Gofrit","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.tranon.2020.100801_bb0275","article-title":"Imaging somatostatin receptor activity in neuroendocrine-differentiated prostate cancer","author":"Mori","year":"2017","journal-title":"Intern. Med. Advance Publication"},{"key":"10.1016\/j.tranon.2020.100801_bb0280","first-page":"29","article-title":"Intraindividual comparison of 68Ga-DOTATATE PET\/CT vs. 111C-choline PET\/CT in patients with prostate cancer in biochemical relapse: In vivo evaluation of the expression of somatostatin receptors","volume":"38","author":"Dos Santos","year":"2019","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"10.1016\/j.tranon.2020.100801_bb0285","doi-asserted-by":"crossref","first-page":"27566","DOI":"10.18632\/oncotarget.4491","article-title":"Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy","volume":"6","author":"Kaemmerer","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2020.100801_bb0290","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.18632\/oncotarget.3242","article-title":"Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms","volume":"6","author":"Kaemmerer","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2020.100801_bb0295","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1007\/s00432-016-2220-6","article-title":"Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin","volume":"142","author":"Stollberg","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.tranon.2020.100801_bb0300","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1038\/s41598-019-39607-2","article-title":"Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin","volume":"9","author":"Mai","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tranon.2020.100801_bb0305","doi-asserted-by":"crossref","first-page":"167","DOI":"10.5534\/wjmh.2014.32.3.167","article-title":"Meta-analysis of the relationship between CXCR4 expression and metastasis in prostate cancer","volume":"32","author":"Lee","year":"2014","journal-title":"World J. Mens Health"},{"key":"10.1016\/j.tranon.2020.100801_bb0310","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.2147\/DDDT.S82475","article-title":"The association of CXCR4 expression with clinicopathological significance and potential drug target in prostate cancer: a meta-analysis and literature review","volume":"9","author":"Chen","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.tranon.2020.100801_bb0315","first-page":"e793","article-title":"Contemporary incidence and cancer control outcomesof primary prostate cancer: a SEER database analysis","volume":"15","author":"Zaffuto","year":"2017","journal-title":"Clin. Genitour. Cancer"},{"key":"10.1016\/j.tranon.2020.100801_bb0320","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3892\/mco.2015.645","article-title":"Neuroendocrine differentiation in castration-resistant prostate cancer","volume":"3","author":"Priftakis","year":"2015","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.tranon.2020.100801_bb0325","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1210\/jc.2014-2699","article-title":"Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers","volume":"100","author":"Kaemmerer","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tranon.2020.100801_bb0330","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1186\/s12885-017-3911-3","article-title":"Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets","volume":"17","author":"Kaemmerer","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tranon.2020.100801_bb0335","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s00432-018-2722-5","article-title":"Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer","volume":"144","author":"Stumpf","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.tranon.2020.100801_bb0340","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1007\/s00432-019-03011-0","article-title":"Somatostatin and chemokine CXCR4 receptor expression in pancreatic adenocarcinoma relative to pancreatic neuroendocrine tumours","volume":"145","author":"Kajtazi","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.tranon.2020.100801_bb0345","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/pros.21383","article-title":"PC3 is a cell line characteristic of prostatic small cell carcinoma","volume":"71","author":"Tai","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.tranon.2020.100801_bb0350","doi-asserted-by":"crossref","DOI":"10.14440\/jbm.2015.63","article-title":"In vitro and in vivo model systems used in prostate cancer research","volume":"2","author":"Cunningham","year":"2015","journal-title":"J. Biol. Meth."},{"key":"10.1016\/j.tranon.2020.100801_bb0355","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/labinvest.3700181","article-title":"CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion","volume":"84","author":"Singh","year":"2004","journal-title":"Lab. Investig."},{"key":"10.1016\/j.tranon.2020.100801_bb0360","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.tranon.2020.100801_bb0365","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41391-019-0134-5","article-title":"MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer","volume":"22","author":"Nickols","year":"2019","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.tranon.2020.100801_bb0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010087","article-title":"Vascular CXCR4 expression \u2014 a novel antiangiogenic target in gastric cancer?","volume":"5","author":"Ingold","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2020.100801_bb0375","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00432-018-2645-1","article-title":"Differential somatostatin, CXCR4 chemokine and endothelin A receptor expression in WHO grade I-IV astrocytic brain tumors","volume":"144","author":"Lange","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.tranon.2020.100801_bb0380","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.3390\/ijms20112676","article-title":"Targeting angiogenesis in prostate cancer","volume":"20","author":"Melegh","year":"2019","journal-title":"Int. J. Mol. Sci."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523320302205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523320302205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:38:28Z","timestamp":1761835108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523320302205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":76,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1936523320302205"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2020.100801","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Somatostatin and CXCR4 Receptor Expression in a Large Set of Prostate Cancer Samples Using Tissue Microarrays and Well-Characterized Monoclonal Antibodies","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2020.100801","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.","name":"copyright","label":"Copyright"}],"article-number":"100801"}}